Aegea Biotechnologies, Inc. Announces Significant Progress on Development of Two Distinct COVID-19 Rapid, Nucleic Acid Based, Diagnostic Tests

    NEXT STORY
    Clinical Experts Discuss Fluid Management Strategies in Critically Ill COVID-19 Patients during CHF Solutions Webinar
    PREV STORY
    PRA Health Sciences ready to navigate RACE Act requirements for pediatric oncology
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Terveystalo Plc: Terveystalo appoints Petri Bono as Chief Medical Officer

    Terveystalo Plc Stock Exchange release 31 December 2018 at 11:45 a.m. EET Petri Bono, ...

    author_avatar
    NASDAQ Market News

    Predictive Oncology Announces $2.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

    author_avatar
    NASDAQ Market News

    AzurRx BioPharma Announces Exclusive Worldwide License Agreement with First Wave Bio for Use of Proprietary Niclosamide Formulations to Treat Immune Checkpoint Inhibitor-Associated Colitis and COVID-19 Gastrointestinal Infections

    author_avatar
    NASDAQ Market News